The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers
| Autor: | A D, Van Haarst, J M, Van Gerven, A F, Cohen, M, De Smet, A, Sterrett, K L, Birk, A L, Fisher, M E, De Puy, M R, Goldberg, D G, Musson |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Cross-Over Studies Monoamine Oxidase Inhibitors Sumatriptan Moclobemide Blood Pressure Triazoles Tryptamines Methoxyhydroxyphenylglycol Serotonin Receptor Agonists Double-Blind Method Area Under Curve Receptor Serotonin 5-HT1D Receptors Serotonin Benzamides Receptor Serotonin 5-HT1B Humans Female Drug Interactions Oxazoles Biotransformation Oxazolidinones Half-Life |
| Zdroj: | British journal of clinical pharmacology. 48(2) |
| ISSN: | 0306-5251 |
| Popis: | The new 5-HT1B/1D agonist rizatriptan (MK-0462) has recently been registered for the treatment of migraine. Its primary route of metabolism is via monoamine oxidase-A (MAO-A). Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes. Hence, this study aimed to investigate the interactions between rizatriptan and moclobemide.In a double-blind, randomized, placebo-controlled, two-period cross-over study 12 healthy, young volunteers (six males, six females) were treated with moclobemide (150 mg twice daily) or placebo for 4 days. On the fourth day, a single dose of rizatriptan (10 mg) was administered, and subsequently blood and urine samples were collected for assay of rizatripan and N-monodesmethyl rizatriptan. Plasma concentrates of 3,4-dihydroxyphenylglycol (DHPG), a marker of MAO-A inhibition, were also assessed. Supine and standing blood pressure were measured regularly.Both treatments were well tolerated. During moclobemide, the increase in supine diastolic blood pressure following rizatriptan administration was augmented. Inhibition of MAO by moclobemide was inferred from a persistent decrease in DHPG level (43% on average). When rizatriptan was coadministered with moclobemide, the area under the plasma drug concentration-time profiles for rizatriptan and its N-monodesmethyl metabolite increased 2.2-fold (90% CI, 1.93-2.47) and 5.3-fold (90% CI, 4.81-5.91), respectively, when compared with placebo. Peak plasma drug concentrations for rizatriptan and its n-monodesmethyl metabolite increased 1.4-fold (90% CI, 1.11-1.80) and 2.6-fold (90% CI, 2.23-3.14), respectively, and half-lives of both were prolonged.Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A. Thus, moclobemide may considerably potentiate rizatriptan action. Concurrent administration of moclobemide and rizatriptan is not recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text